Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.
Research output: Contribution to journal › Journal article › Research › peer-review
In vivo production and systemic delivery of therapeutic antibodies by engineered cells might advantageously replace injection of purified antibodies for treating a variety of life-threatening diseases, including cancer, acquired immunodeficiency syndrome, and autoimmune diseases. We report here that skin fibroblasts retrovirally transduced to express immunoglobulin genes can be used for sustained long-term systemic delivery of cloned antibodies in immunocompetent mice. Importantly, no anti- idiotypic response against the ectopically expressed model antibody used in this study was observed. This supports the notion that skin fibroblasts can potentially be used in antibody-based gene/cell therapy protocols without inducing any adverse immune response in treated individuals.
Original language | English |
---|---|
Journal | Journal of Investigative Dermatology |
Volume | 115 |
Issue number | 4 |
Pages (from-to) | 740-5 |
Number of pages | 5 |
ISSN | 0022-202X |
DOIs | |
Publication status | Published - 2000 |
Bibliographical note
Keywords: Animals; Antibodies, Monoclonal; Antibody Formation; Disease Models, Animal; Fibroblasts; Gene Therapy; Humans; Immunocompetence; Mice; Skin
ID: 5644042